Clinical Trials Browser

Phase 1/2 × Solid Tumor × 1 year × Clear all

NCT05262530 2026-04-08

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Phase 1/2 Terminated

Other solid neoplasm

Solid Tumor

NCT07446153 2026-04-03

A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT06166836 2026-03-25

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT07229638 2026-03-20

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07466160 2026-03-12

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04939610 2026-03-11

LuMIERE

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06384807 2026-03-11

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07069062 2026-03-09

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06667960 2026-03-05

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07392736 2026-02-06

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07382531 2026-02-04

OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06631079 2026-01-08

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT04175847 2026-01-07

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor

NCT05174585 2026-01-06

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor

NCT06198426 2025-12-30

A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Other solid neoplasm

Solid Tumor

NCT06712680 2025-12-23

A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07229586 2025-12-19

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07258121 2025-12-02

Study of ZGGS34 in Participants With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT06220318 2025-11-28

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05991349 2025-11-25

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor

NCT07245901 2025-11-24

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT06212076 2025-09-24

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Phase 1/2 Completed

37 enrolled 32 charts

Other solid neoplasm

Solid Tumor

NCT06468358 2025-09-11

TRIGGERCD8

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT02992210 2025-09-08

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07140393 2025-08-24

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT04455620 2025-07-02

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Phase 1/2 Terminated

49 enrolled 19 charts

Other solid neoplasm

Solid Tumor

NCT06603844 2025-06-03

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06234098 2025-05-02

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06949761 2025-04-29

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor